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Matrix-assisted laser desorption/ionizationmass spectrometry imaging (MALDI-MSI) is amass
spectrometry technique used for the analysis of macromolecules on an intact tissue of interest,
thereby allowing the assessment ofmolecular signatures in health and disease in the anatomical
context. MALDI-MSI is increasingly used to investigate neurodegenerative and psychiatric
disorders at the molecular level, including Alzheimer’s disease (AD), Parkinson’s disease (PD),
and schizophrenia (SCZ). These illnesses are characterized by complex neuropathological
processes, and conventional proteomic techniques investigating brain tissue homogenates have
inherent limitations in determining the precise anatomical or cellular location of proteomic
findings. In this article, we review MALDI-MSI studies on neurodegenerative and psychiatric
disorders, and explore whether the technique could accelerate the translation of proteomic
information into improved understanding and ultimately better therapeutic applications.
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1 Introduction
Neurodegenerative disorders such as Alzheimer’s disease
(AD) and Parkinson’s disease (PD), and psychiatric disorders
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Abbreviations: 6-OHDA, 6-hydroxydopamine; ACh, acteylo-
choline; AD, Alzheimer’s disease; ALS, amyotrophic lateral scle-
rosis; APP, amyloid precursor protein; CSF, cerebrospinal fluid;
DA, dopamine; DHA-PC, docosahexaeonic acid containing phos-
phatidylcholines; DPP-TFB, 2,4-diphenyl-pyranylium tetrafluo-
roborate; FAD, familial Alzheimer’s disease; FFPE, formalin-
fixed paraffin embedded; GABA, -amino butyric acid; GLU,
glutamate; hSOD1, human superoxide dismutase 1; LBs,
Lewy inclusion bodies; L-DOPA, L-3,4-dihydroxyphenylalanine;
LID, L-DOPA-induced dyskinesia; MAO-B, monoamine oxi-
dase B; MPAQ, 2-methyl-3-phenyl-6-amino-quinoxaline; MPP+,
N-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; ND, neuropsychiatric disorders; PC, phos-
phatidylcholine; PD, Parkinson’s disease; PEP-19, Purkinje cell
protein 4; SCZ, schizophrenia; SNpc, substantia nigra pars com-
pacta; SOD, superoxide dismutase; Ubc-T, truncated ubiquitin
such as schizophrenia (SCZ), are thought to represent the
largest contributor to all-cause disease burden in developed
countries [1]. For many sufferers, these illnesses take a
chronic course and lead to functional cognitive decline and
loss of independence.
Despite decades of scientific inquiry, the molecular mech-
anisms driving the aetiopathology of these devastating disor-
ders remain incompletely understood, and treatments remain
largely non-specific and palliative rather than curative (for ex-
ample, see [2, 3]). One of the reasons for this relative lack of
scientific progress is that the CNS is a most complex struc-
ture, with an extraordinarily high degree of inter-connectivity
and interaction within and between brain regions. Native
and pathological processes in the CNS rely on translocation
and concentration gradient formation of molecules in time.
Therefore, in studying changes of these analytes in the CNS
in relation to psychiatric disorders and neurodegenerative
disorders, it is pivotal to ensure a reliable representation of
their spatio-temporal distribution in health and disease.
Proteomic, metabolomic, and lipidomic techniques offer a
potential avenue towards better understanding of processes
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underpinning disorders of the brain. Through their ability
to simultaneously quantify large numbers of molecules in
a given biological substrate, these techniques can uncover
disease-related pathways and processes previously invisible
to purely hypothesis-driven research. Consequently, a large
number of studies have been undertaken that profile post-
mortem brain tissue, cerebrospinal fluid (CSF), and periph-
eral body fluids such as blood serum or plasma of patients
with neurodegenerative and psychiatric disorders. However,
for post-mortem brain investigations in particular, the chal-
lenge remains that most studies have worked with tissue
homogenates of brain areas of interest, which inherently can-
not provide information of the exact anatomical or cellular
location of the detected molecular abnormalities. Further,
a comparison of common proteomic post-mortem findings
in various neurodegenerative and psychiatric conditions in-
dicates that there is a large overlap in the molecular path-
ways and processes apparently implicated in disease patho-
physiology. For example, aberrant proteins and pathways
involved in oxidative stress, mitochondrial function, energy
metabolism, the cytoskeleton, and the synapse have been re-
ported in PD [4,5], AD [6,7], and in psychotic illnesses includ-
ing schizophrenia and bipolar disorder [8–12]. It is not clear
whether these overlapping findings reflect true mechanistic
commonalities relevant to chronic brain conditions [13, 14],
or whether they are a consequence of “de´ja` vu proteomics”
where similar findings for diverse disorders may be a reflec-
tion of technical shortcomings and biases rather than actual
biological discoveries [15, 16]. Because of these difficulties, it
is of little surprise that the development of clinical diagnostics
based on proteomic findings in neurodegenerative and psy-
chiatric disorders has remained relatively unproductive and
controversial [17].
One established in vitro technique that could contribute
to improving this situation is matrix assisted laser desorp-
tion/ionization mass spectrometry imaging (MALDI-MSI).
MALDI-MSI provides molecular mass determination of ana-
lytes from complex mixtures (e.g. tissue) while keeping their
spatial distribution intact [18]. This allows for the creation
of m/z images, where the location and intensity of distinct
m/z values correspond to morphological and/or patholog-
ical features of the analysed sample (for a recent review
see [19]). This constitutes the advantage of MALDI-MSI in
comparison with “classical” proteomic, metabolomic, and
lipidomic techniques, which normally involve a homogeniza-
tion step and therefore the loss of spatial information within
the analysed samples. Further, MALDI-MSI has the poten-
tial to represent a true -omics technique that is independent
of a priori specified target molecules, in contrast to other in
vitro imagingmethods such as antibody-based immunohisto-
chemistry. Additionally, MALDI-MSI can be used to replace
immunohistochemistry-based quantitive analyses of proteins
of interest, providing a faster and reliable method that does
not require stereologic cell counting procedures.
Proteomic investigation of CNS tissue samples in neurode-
generative and psychiatric disorders byMALDI-MSI has been
an advancing field over the last decade, and the technique
has been applied to human post-mortem tissue as well as
to established mouse models of these diseases. In this arti-
cle, we review how MALDI-MSI has been used to advance
and complement neuropathological knowledge and previous
proteomic, metabolomic, and lipidomic investigations in the
major neurodegenerative and psychiatric illnesses. We also
point out the potential of MALDI-MSI for future studies.
2 MALDI-MSI: the technique in a nutshell
MALDI-MSI is a technique where tissue sections get
mounted onto electrically conductive slides, spray coatedwith
matrix and rastered by a laser beam to acquire mass spectra
of analytes of interest (most commonly proteins, peptides,
metabolites, small molecules or lipids [20]) (see Fig. 1). This
technique was firstly introduced by Caprioli et al. in 1997
[18]. Depending on the tissue and analyte of interest, differ-
ent matrices and sample preparation steps have to be applied.
Protein imaging is normally being conducted on fresh frozen
tissues, using sinapinic acid as a matrix and only minimal
sample preparation is necessary (for a review see [21]). This
basically also applies for lipid imaging [21]. Peptide imaging
can be conducted on fresh frozen, but most importantly on
formalin-fixed paraffin embedded (FFPE) tissues [22]. The
Figure 1. MALDI-MSI of brain tissue sections following MPTP
treatment. Panels a-b show the photographs of mouse brain
hemispheres from one control and one MPTP treated animal,
respectively, mounted on a gold-coated stainless steel plate
(str = striatum). Panels c-d display the same tissue sections spot-
ted with matrix solution (SA, 50:50:0.1 ACN:H2O:TFA). The di-
ameters of the matrix spots are about 190 m and the distance
from center to center is 280 m. Panels e-f show the ion den-
sity of PEP-19. The distribution and relative intensity difference
between control and MPTP treatment is representative for the
analysed tissue sections. Reprinted with permission from Skold,
K., Svensson, M., Nilsson, A., Zhang, X. et al., Decreased striatal
levels of PEP-19 following MPTP lesion in the mouse. J. Pro-
teome Res. 2006, 5, 262–269. Copyright 2006 American Chemical
Society.
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ability to investigate FFPE tissue makes vast libraries of clin-
ical tissue specimen available for analysis by MALDI-MSI
(reviewed in [23]). However, sample preparation for peptide
imaging from FFPE tissues is complex. Generally, an antigen
retrieval step has to be applied to reverse protein cross-linking
caused by formalin [24] (for a review see [23]), followed by a
tryptic digest. Advantageous is the application of internal cal-
ibrants to increase mass accuracy of detectedm/z features, as
this improvesmatching of peptides betweenMALDI-MSI and
LC-MS/MS for identification purposes [25]. In recent years,
MALDI-MSI has been extended to the analysis of N-glycans
[26], which enables investigation of differentially expressed
glycan species in relation to tissue type [26–29].
3 Applications of MALDI-MSI in
neurodegenerative and psychiatric
disorders research
MALDI-MSI is an emerging technique and therefore only
a limited number of specialist laboratories apply this tech-
nique. This is evidenced by the small number of studies in
the field of ND research featuring this technology. Further,
ND research faces unique challenges: Human samples of ND
are very rare as they can only be acquired post-mortem; there-
fore animal models have to be applied. This further limits the
number of ND which can be investigated, as development
of animal models of complex psychiatric disorders such as
schizophrenia [30, 31] or depression [32] are a challenging
task [33]. This is reflected in the number of publications
regarding the type of ND, PD being the most studied, fol-
lowed by AD. Apart from MALDI-MSI, other imaging tech-
nologies like laser-ablation inductively coupled plasmaMS or
secondary ion MS have been applied in ND, however these
investigations were considered out of scope for this review.
For comprehensive reviews of these technologies for neuro-
science applications see [34] and [35].
3.1 Parkinson’s disease
PD is a neurodegenerative disorder leading to progressive
motor disability through body tremors, slowed movement,
muscle rigidity, and an irregular posture [36]. Genetically,
PD appears to differentiate into rare familial forms that show
associations with autosomal dominant and autosomal reces-
sive loci and intomore common ‘idiopathic’ illness types with
a complex polygenetic signature [37]. Neuropathologically,
all forms of PD are characterized by the loss of dopamin-
ergic neurons in the substantia nigra pars compacta (SNpc),
and by the development of intracellular Lewy inclusion bod-
ies (LBs) containing -synuclein [38]. This is pointing to
an impairment of a selected group of neurons in the han-
dling of abnormally processed cellular proteins and a subse-
quent deposition of those proteins as insoluble and toxic ag-
gregates. Molecular and proteomic investigations of human
SNpc and LBs have, in summary, implicated oxidative stress,
mitochondrial dysfunction, protein aggregation, and the
ubiquitin-proteasome system as potential pathways relevant
to PD pathophysiology [5, 39–43] (reviewed in [4]). However,
how these candidate cellular processes drive LB development
and dopaminergic degeneration within the relevant brain
areas and neural networks, and how they are affected by
common treatments such as L-3,4-dihydroxyphenylalanine
(L-DOPA), is not well understood. Proteomic studies utilizing
MALDI-MSI have begun to provide additional information on
these questions.
3.1.1 Animal models of PD and MALDI-MSI
In proteomic research using MALDI-MSI, a number of PD
animal models have been studied to date. One model in-
vestigated by MALDI-MSI studies uses unilateral injection
of 6-hydroxydopamine (6-OHDA) by stereotaxic surgery into
SNpc, where it causes degeneration of dopaminergic neu-
rons following uptake via dopamine and noradrenaline trans-
porters [44–46]. The toxicity of 6-OHDA is derived from its
oxidation by monoamine oxidase B (MAO-B), which pro-
duces hydrogen peroxide [47]. Further, 6-OHDA undergoes
auto-oxidation, which produces hydrogen peroxide, reactive
oxidative species and catecholamine quinonones [48, 49].
Mitochondrial function is affected as well by 6-OHDA, as
the function of complex I of the electron transport chain is
impaired [45].
Another model of PD investigated by MALDI-MSI
uses systemic administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), which reproduces all clinical
manifestations of PD in primates, however without the devel-
opment of Lewy inclusion bodies (reviewed in [50]). In con-
trast to 6-OHDA,MPTP easily crosses the blood-brain barrier
and is subsequently oxidized in astrocytes [51] into N-methyl-
4-phenylpyridinium (MPP+) by MAO-B [51, 52]. MPP+, as
the actual neurotoxic compound, is accumulated intracellu-
larly by the presynaptic re-uptake system [53, 54], and causes
inhibition of the electron transport bymitochondrial complex
I and, ultimately, cell death [55, 56].
MALDI-MSI studies of PD animal models have addressed
the following research questions: (i) to validate animal mod-
els of PD; (ii) to complement targeted investigations on the
differential expression of PD candidate proteins in different
brain areas of PD rodents [57]; (iii) to identify differential
proteomic effects of L-DOPA in various brain regions of PD
animals [58, 59]; (iv) to map changes in neurotransmitters in
PD; (v) to identify the spatial distribution of novel PD drugs
in rodent brain.
(a) Targeted MALDI-MSI for the validation of PD animal
models
Investigating the clinical validity of the MPTP model,
Kadar et al. applied MALDI-MSI to investigate the distribu-
tion of the neurotoxic component MPP+ in mouse brain
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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after intranasal application of MPTP [60]. Ion images for the
m/z of 170.1, corresponding to MPP+, recorded with a spa-
tial resolution of 70 m showed that the compound could be
detected in almost the entire brain 10 min following MPTP
administration, whereas after 90 min MPP+ was found pre-
dominantly concentrated in dopaminergic areas, including
the SNpc, thus strongly supporting intranasal MPTP admin-
istration as a valid model for PD research.
(b) Targeted MALDI-MSI investigations of PD-associated
proteins in animal models
Nilsson et al. addressed the question whether the im-
munophilin protein FKBP-12, a binding partner of the ex-
perimental PD drug FK506 and thought to possess neuro-
protective and neuroregenerative properties in experimental
PD models [61], shows an anatomically differential expres-
sion pattern in the striatum of 6-OHDA unihemispherically
lesioned rat brain [57]. Using MALDI-MSI, the authors re-
ported that FKBP-12 (m/z 11 791) ion intensity was elevated
in the dorsal and medium part of lesioned rat striatum, but
unchanged in the ventral part [57].
Demonstrating similar anatomical differences with re-
gards to striatal protein changes following 6-OHDA le-
sion, Pierson et al. reported increased levels of ubiquitin
(m/z 8565), a protein that accumulates in LBs, in the dor-
sal but not the ventral rat striatum affected by 6-OHDA [59].
The authors speculate that these anatomical differences could
be either due to lower dopaminergic innervation of the ven-
tral striatum, or to lower efficacy of the 6-OHDA lesion in
this area. It is of value to note that in previous studies us-
ing homogenized samples from human SNpc [39] and from
6-OHDA treated rats [62], changes in brain ubiquitin levels
could not be detected, highlighting the potential advantages
of MALDI-MSI over conventional proteomic techniques.
A similar study using MALDI-MSI investigated the ex-
pression levels of Purkinje cell protein 4 (PEP-19), a protein
thought to possess anti-apoptotic properties in neurodegen-
erative disorders [63–65] in the brains of C57BL/6 after subcu-
taneous injection of MPTP [66]. Anatomical and quantitative
analysis of PEP-19 ion intensity by MALDI-MSI (spatial res-
olution = 280 m) revealed that PEP-19 expression is mostly
restricted to the striatum, with a significant decrease in ex-
pression area in case of MPTP treated mice [66] (Fig. 1).
(c) MALDI-MSI experiments to identify differential pro-
teomic effects of L-DOPA on various brain regions of
PD animals
Pierson et al. conducted a MALDI profiling study inves-
tigating the effects L-DOPA on 12 brain regions of inter-
est in 6-OHDA treated rats [58]. Seven m/z features ex-
hibited differential expression (student’s t-test p< 0.05) be-
tween corresponding locations in the two hemispheres in the
L-DOPA treated group but not in the saline control. Five of
these differentially expressed peptides were located to the
6-OHDA-lesioned striatum, and three striatal features could
be identified as under-expressed calmodulin and cytochrome
c oxidase subunit VIIa-L and as cytochrome c oxidase. Fur-
ther, an increased ratio of PTMsuch as acetylationswas found
in the striatum of proteins in the dopamine depleted side of
the brain, an effect that was attenuated following L-DOPA
treatment.
TwoMALDI-MSI studies have investigated a common and
serious side-effect of L-DOPA treatment seen in PD patients,
L-DOPA-induced dyskinesia (LID). In a targeted approach,
the spatial ion distribution of peptide masses correspond-
ing to endogenous opioid neuropeptides (endogenous dynor-
phins), thought to mediate LID in humans and rodents, was
examined in the brains of 6-OHDA- and L-DOPA treated rats
[67, 68]. Both studies applied DHB as matrix using an inkjet
printer on 12 m brain slices, however the resolution dif-
fered between 250 [68] and 300 m [67]. Both studies report
the up-regulation of dynorphin B and alpha neoendorphin
in the lesioned striatum [67] and substantia nigra [68] in an-
imals showing high dyskinesia behaviours compared to the
low dyskinesia and saline control groups. Additionally, a lin-
ear correlation between expression levels of the differentially
expressed neuropeptides and the severity of dyskinesia is re-
ported in both studies. In the striatum, substance P was addi-
tionally up-regulated in the high dyskinesia group [67], while
in the substantia nigra Leu-Enk-Arg was increased [68].
(d) MALDI-MSI to map changes in neurotransmitters in PD
A further study by Shariatgorji et al. applied a novel ap-
proach to detect low molecular weight compounds such as
dopamine (DA), -amino butyric acid (GABA), glutamate
(GLU) and acteylocholine (ACh) in the brains of sham le-
sioned, 6-OHDA lesioned and D3-L-DOPA (after 6-OHDA
lesion) treated rats [69]. The novel approach was to derivatise
primary amines with 2,4-diphenyl-pyranylium tetrafluorob-
orate (DPP-TFB) to enable their ionization by laser energy
without the further assist of a matrix and achieves a remark-
able spatial resolution of 15 mwhich achieves visualization
of the nuclei of the facial nerves and pons [69] (Fig. 2). In
6-OHDA lesioned animals, the authors found decreased stri-
atal levels ofDA and increased striatal levels ofGABA,mirror-
ing findings in humans with PD. This approach was further
investigated using a primate model of MTPT lesion, where
differential distribution of DA, 3-methoxytyramine and
GABA in coronal brain tissue sections were detected [69].
The quantification was achieved by comparing the signal
intensities of analytes of interest with known quantities of
deuterated calibration standards. Additionally, it was shown
that the use of deuterated HCCA matrix can be successfully
applied to overcome masking effects of matrix compounds
with the samem/z as analytes of interest such as ACh, which
lack a primary amine [69].
(e) MALDI-MSI experiments to detect the spatial distribu-
tion of novel PD drugs in rodent brain.
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
Proteomics 2016, 16, 1747–1758 1751
Figure 2. High-resolutionMALDI-MS Images of ACh in a Sagittal Rat Brain Section (A–F) MALDI-MS images of ACh in a rodent brain sagittal
tissue section. The relative distribution and abundance of ACh determined by MS imaging are consistent with existing data on the major
cholinergic pathways in the brain (A). ACh-rich structures such as the HIPP, CP, CTX, and even small structures such as the nuclei of the facial
nerves and pons are readily apparent in the MALDI-MS image. High-resolution MALDI-MS images (15 m spatial resolution) of various
structures in consecutive brain tissue sections were also acquired. Substructures of the hippocampus were delineated by high-resolution
imaging of the distribution of a lipid withm/z 721.2 (B). The relative abundance and distribution of ACh in the HIPP (C), a subregion of the
CP indicated by a dashed rectangular border in (A) (D), and CB (E) were determined by high-resolution imaging. The concentration of ACh
in the gray matter of CB is around five times greater than that in the white matter. In the HIPP, high ACh concentrations are apparent in
DG-sg and sp regions (F). MS images were acquired using a MALDI TOF/TOF mass spectrometer. Data are shown using a rainbow scale
and are normalized against the total ion counts; scale bars, 2, 1, and 500 mm; spatial resolutions = 100 and 15 mm. Caudate-putamen,
CP; hippocampus, HIPP; cerebellum, CB; granule cell layer of the dentate gyrus, DG-sg; pyramidal layer of CA1, sp; cerebral cortex, CTX;
piriform area, PIR; striatum (ventral region), STRv; thalamus, TH; subiculum, SUB; stratum lacunosum-moleculare, Slm; stratum radiatum,
Sr; stratum oriens, So; cornu ammonis (field 2), CA2; cornu ammonis (field 3), CA3; polymorph layer of dentate gyrus, PO. Reprinted
from Neuron 84 (2014), Shariatgorji, M., Nilsson, A., Goodwin, R. J., Kallback, P. et al., Direct targeted quantitative molecular imaging of
neurotransmitters in brain tissue sections. Pages 697–707, Copyright 2014, with permission from Elsevier.
MALDI-MSI has been used to investigate the localiza-
tion of novel drugs thought to counteract PD development
or progression in the brain. Quinoxaline derivatives such as
2-Methyl-3-Phenyl-6-Amino-Quinoxaline (MPAQ) reportedly
possess such neuroprotective properties for dopaminergic
CNS neurons [70]. A MALDI-MSI experiment in MAPAQ
treated mice was carried out, using a HCCA matrix applied
onto 14 m thick brain sections, with a distance of 70 m
between acquisition sites [70]. MPAQ (m/z 237.1) was lo-
calized mainly to striatum and the ventral mesencephalon,
which contains the SNpc [70]. Findings support MAPAQ as
a suitable candidate for neuroprotective therapy in PD.
There is currently no published study investigating PD
in human post-mortem brain using MALDI-MSI, and given
the relatively extensive use of the technique in studies of
PD mouse models, future translational opportunities in this
disorder are obvious.
3.2 Alzheimer’s disease
AD is a common neurodegenerative disorder causing pro-
gressive decline of cognitive functions, particularly memory.
Neuropathologically, AD is characterized by the formation of
senile plaques, neurofibrillary tangles, and by synaptic dis-
ruption and neuronal loss. According to the amyloid cascade
hypothesis of pathological origin, aggregation and deposition
of amyloid precursor protein cleavage products (amyloid-
peptides) are causative for neurotoxicity and subsequently af-
fect the protein tau, which in its hyperphosphorylated form
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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is a major constituent of neurofibrillary tangles (reviewed in
[71]).
Similar to the situation in PD research, MALDI-MSI has
been mostly limited to studying mouse models in preclinical
marker research or for drug imaging, and the technique is
yet to realize its full potential in complementing the rich
proteomic literature of 2Dgel electrophoresis and LC-MS/MS
(reviewed in [7] and [72]) in post-mortem AD brain.
The following research questions inAD researchhave been
addressed by MALDI-MSI studies to date: (i) localization of
amyloid- isoforms; (b) changes in the lipidome related to
AD in humans; (c) changes in the lipidome related to AD in
mouse models and (d) investigation of drug distribution in
the brain.
(a) Localization of amyloid-  in mouse models of AD
The general suitability of MALDI-MSI to contribute to AD
research was established by Stoeckli et al., using fresh frozen
brain sections of APP23 transgenic mice [73], a frequently
used AD model based on the overexpression of human amy-
loid precursor protein (APP) exhibiting the Swedish muta-
tion [74, 75]. APP23 mice show first deposits of amyloid-
plaques in neocortex and hippocampus after 6 months [75].
Further, hyper-phosphorylated tau is located only in con-
gophilic plaques [75]. This mouse model is therefore an ideal
candidate to study over-expression of amyloid- peptides as
an Alzheimer’s model. Sinapinic acid was used as a matrix to
identify m/z features corresponding to amyloid- peptides.
By slow crystallization at low temperature, matrix crystals
with a size of up to 200 m were grown and rastered by a
laser every 100 m. Subsequently, m/z features of interest
corresponding to amyloid- isoforms (1-37, 1–38, 1–39, 1–40
and 1–42) were compared with sections immunostained with
NT11 antiserum, detecting amyloid- residue 1–40 [76]. m/z
features of amyloid- isoforms and immunostaining signals
could be reasonably well spatially matched.
(b) MALDI-MSI of lipids in human AD post-mortem tissue
Although generally applied for protein and peptide analy-
sis, changes in the distribution of lipids can also be detected
by MALDI-MSI. Yuki et al. investigated the distribution of
hydroxylated and non-hydroxylated sulphatide species of the
sphingolipid sulphatide in post-mortem human brain [77].
Reductions of sulphatide, a major component of the myelin
sheath, has been reported as a potential early pathological
characteristic in AD and may be one molecular mechanism
underlying the cortical demyelination and oligodendrocyte
degeneration seen in the disorder [78]. Detected by MALDI-
MSI applying a spatial resolution of 100 m, the ratio of
hydroxylated to non-hydroxylated sulphatide species differed
most at the border of white to grey matter AD and healthy
control brains, with no detectable differences in species dis-
tribution between the two groups [77]. Whilst in need of
replication, these results suggest thatmechanisms other than
Figure 3. The distributions and intensities of PC species in coro-
nal sections of non-AD and AD brains as analysed byMALDI-MSI.
Scale bar equivalent to 1 cm. Adapted from Yuki, D., Sugiura, Y.,
Zaima, N., Akatsu, H. et al., DHA-PC and PSD-95 decrease after
loss of synaptophysin and before neuronal loss in patients with
Alzheimer’s disease. Sci Rep 2014, 4, 7130. Under Creative Com-
mons license (CC BY 4.0) (http://creativecommons.org/licenses/
by/4.0/).
sulphatide species generation throughhydroxylationunderlie
sulphatide abnormalities in AD.
In a subsequent study, the authors investigated the distri-
bution of species of docosahexaeonic acid containing phos-
phatidylcholines (DHA-PC) in AD patients brains compared
to normal controls (spatial resolution = 50 m) [79]. Re-
duced levels of DHA-PCs, which are major brain lipid con-
stituents regulating membrane fluidity, had previously been
reported in AD cerebral tissue [80]. Lower relative intensi-
ties of DHA-PC (16:0/22:6) and (18:0/22:6) in grey matter
in brains affected by AD was detected in the temporal, pari-
etal and frontal lobe, while relative intensities of DHA-PC
(16:0/16:0) were not changed (Fig. 3). Further, a correlation
of reduced DHA-PC (18:0/22:6) with the disease duration
in AD as well as earlier age of death was identified [79]. It
was speculated by the authors that the lower intensity of
DHA-PC in AD patients brain influences neuronal cell death,
as cleavage products of DHA-PC can act as anti-apoptotic
factors [81].
(c) Detection of lipid changes in mouse models of AD
A further study byHong et al. investigated changes in phos-
pholipids in 5XFAD mice [82]. These mice are a very rapid
on-set Familial Alzheimer’s disease (FAD) model exhibit-
ing three mutations in amyloid precursor protein (Swedish,
Florida and London) and two mutations in presenilin1
(M146L and L286V) [83]. The rapid on-set is reflected in the
large deposits of A-42, overexpression of p25 and neuronal
loss these mice show after 2 months [83]. MALDI-MSI was
conducted on fresh frozen brain slices of three mice at age
of 3 and 9 months and compared against age matched con-
trol mice. As matrix a 1:1 mixture of HCCA and DHB was
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applied and spectra were acquired in both positive and neg-
ative ion mode with a lateral resolution of 150 m. Brain
regions first to accumulate amyloid plaques showed marked
decrease in phospholipid abundance of PC32:0 in frontal cor-
tex and, PC32:0, SMd34:1 andPC34:1 in the subiculum,while
LPC16:0 was increased in both frontal cortex and subiculum
of 9 months of 5XFAD mice [82]. However, a co-localization
of these features with amyloid plaques was not shown.
(d) MALDI-MSI experiments to detect the spatial distribu-
tion of novel AD drugs in transgenic rodent brain
As described previously, MALDI-MSI is a powerful ap-
proach to test the localization of low molecular weight com-
pounds that have possible therapeutic potential. Spatial distri-
bution of Clioquinol, a “metal attenuating compound” with
proposed therapeutic properties in AD, was investigated in
the brains of treated TgCRND8 mice [84]. These mice exhibit
the Swedish and Indiana mutation of the amyloid precursor
protein 695, accumulate cerebral amyloid-plaques and show
marked workingmemory deficits at a young age, thereby rep-
resenting a suitable model of early onset AD [85]. Clioquinol,
in this model, reverses the behavioural deficits and reduces
amyloid- plaque burden in the cortex and hippocampus.
MALDI-MSI visualization of the clioquinol diagnostic signal
using a HCCAmatrix that was air-brushed onto 10 m brain
sections; data was acquired with a resolution of 250 m in re-
flectron positivemode.Detection of the clioquinol signal (m/z
305.9) revealed that the drug was enriched specifically in the
cortex and hippocampus [84], two brain areas prominently
involved in the cognitive function affected by AD pathology.
Hence the authors interpreted these findings as support for
the potential of metal attenuating agents in AD therapy, and
for the role of biometals such as zinc, copper, and iron such
in the formation of amyloid- plaques. The study thus com-
plements previous findings that these ions are enriched in
plaques in human AD brain as well as in AD mouse models
[86–89].
3.3 Schizophrenia
Only one pilot MALDI-MSI study to date has examined post-
mortem brain tissue of patients with schizophrenia [90].
In a two-step approach, the authors first characterized and
compared lipid species in homogenized brain tissue of a
schizophrenia case and healthy control. Subsequently, lipid
species differentially expressed in the homogenized control
and diseased brains were screened for in the mass spectra
obtained from a MALDI-MSI experiment imaging the pre-
frontal cortex. The authors reported abnormal distributions
of a phosphatidylcholine (PC) molecular species particularly
in the cortical layer of the frontal cortex in schizophrenia,
compared to a matched healthy control brain. Additionally, a
PC containing arachidonic acid was increased in the frontal
cortex of the schizophrenia patient.
Whilst it is difficult to draw scientific conclusions from this
experiment, due to an experimental sample size of two and
several potential confounders that had not been controlled
for, the study complements previous findings that implicate
abnormal brain lipid compositions in schizophrenia [91, 92].
The demonstrated ability of MALDI-MSI to detect such lipid
changes in an anatomical context represents a major techno-
logical advance.
3.4 Amyotrophic lateral sclerosis (ALS)
ALS is a fatal progressive, degenerativemotor neuron disease
(reviewed in [93]). The origin of the disease is unknown and
current consensus is that underlying genetic causes are due
to rare traits leading to a common disease pathomechnism
[93]. Common mutations encountered in familial ALS affect
superoxide dismutase (SOD)1 [94], which gave the incentive
for Acquadro et al. to investigate the effects of mutant human
SOD1 (G93A hSOD1), wild type human SOD1 (hSOD1), and
murine SOD1 in the brain of transgenic and non-transgenic
mice [95]. Applying MALDI-MSI, G93A hSOD1 was detected
to be restricted to facial nuclei, while hSOD1 and murine
SOD1 showed no preferential localization. Within the facial
nuclei, 40S ribosomal protein S19 was detected to be up-
regulated in G93A hSOD1 compared to hSOD1 and non-
transgenic mice [95]. This protein is of special interest, as
it has been shown to interact with fibroblast growth factor
2 [96, 97], which is involved in motor neuron development,
maintenance and repair [98, 99].
The only study, published to date in the field of neu-
rodegenerative disorders, that employed MALDI-MSI tech-
nology for hypothesis-free profiling of human post-mortem
tissue, investigated human spinal tissue from patients with
ALS [100]. Here, post-mortem spinal cord sections of four
ALS patients and three healthy controls were analysed with
a spatial resolution of 350 m for global differential protein
expression. A truncated form of ubiquitin (Ubc-T) and an
unidentified m/z feature of 8429 were found to be under-
expressed in ALS spinal cord compared to healthy controls.
The authors additionally describe that full-length ubiquitin
localizes to the dorsal horn of human spinal cord, while the
truncated form Ubc-T is evenly distributed throughout the
grey matter, pointing to a region-specific defect of specific
ubiquitin isoforms in ALS. This finding, specific to a distinct
protein isoform in a distinct anatomical region, represents a
major advance towards the understanding of potential ubiq-
uitin pathology in the disease, and highlights the opportuni-
ties of MALDI-MSI investigations in neurodegenerative and
psychiatric disorders.
4 Concluding remarks
Over the last decade, biomedical research into neurodegen-
erative and psychiatric disorders has gradually begun to
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integrate MALDI-MSI into studies aiming at the targeted de-
tection of proteins, lipids, neuropeptides, and small molecule
therapeutics in human and animal CNS tissue. Our review
of published studies indicates that the technique is still at an
early stage in the neurosciences, and that its full potential
remains to be realized for neurodegenerative and psychiatric
disorders. Nevertheless, a small number of research groups
have made considerable inroads into the investigation of dis-
orders of the brain using MALDI-MSI, particularly in the
fields of PD and AD. Our overview of the current literature
highlights the opportunities for this novel technology in neu-
roscience research.
In the targeted studies summarized in this article inves-
tigating expression levels of selected proteins, lipids and
drugs in human or animal brain, MALDI-MSI has provided a
considerable methodological advantage over conventional
quantitative techniques. Examining protein, lipid or drug
distribution in intact tissues by immunohistochemistry or
radiography for radiolabelled drugs are time consuming (ad-
ditionally to their synthesis), require stereological counting of
immunolabelled structures for proteins, and have a limited
dynamic range. Further, metabolites of radiolabelled drugs
might escape detection. Additionally, mass spectrometry can
distinguish between metabolic fragments, conjugated pro-
teins and post-translational modifications, an ability that im-
munological techniques generally do not possess.
While other state-of-the-art proteomic methods like LC-
MS/MS of homogenized tissues can identify thousands of
proteins and are capable to detect significant differential ex-
pression in hundreds of them, MALDI-MSI can only provide
this for a couple of hundred proteins/peptides. However,
being able to accurately access the proteome in a spatially re-
solved point of the investigated tissue is amajor advantage, al-
lowing identification and quantification of changes in minis-
cule, restricted parts of tissue/cells corresponding to disease.
This stands in contrast to classical proteomic methods
applying tissue homogeniation, which can only detect gross
changes, affecting large parts of the tissue which avoid nor-
malization of expression changes by the unaffected parts of
the sample. Although smaller affected areas can be sampled
by e.g. laser micro-dissection, the resolution of this method
is limited by the protein amount that can be extracted for sub-
sequent analysis. Therefore, MALDI-MSI offers the unique
chance to identify molecular mechanisms of changes in early
stages of disease, where only small parts of tissue are affected,
while avoiding protein/peptide losses due to extensive sam-
ple preparation applied in non in-situ methods. This renders
MALDI-MSI a primemethodology to be used in neuroscience
not only in a targeted fashion, but as a true –omics technology.
It is important to mention that there have been consider-
able barriers towards a more widespread use of MALDI-MSI
in neurology and psychiatry. Firstly, the technology is ex-
pensive and extremely labour and computationally intense,
thereby severely limiting experimental sample sizes that can
be assessed. In the studies published to date, experimen-
tal groups routinely consist of one to five specimen, which
is hardly enough to serve as a representative model of the
clinical population. Secondly, the technique requires consid-
erable expert knowledge and access to state of the art MS
instruments; both are not routinely available to biomedical
researchers. Thirdly, as mentioned above, the depth of the
coverage of the proteome reflecting disease is limited com-
pared to other –omics technologies. As fourth consideration,
MALDI-MSI investigations have focused on the analysis of
fresh frozen brain tissue, which is however hard to preserve
and is therefore difficult to obtain from human brain banks.
Lastly, animal model systems can ultimately only be approx-
imations of human neurodegenerative and psychiatric dis-
eases in terms of their genetic complexity and subsequent
consequences in terms of transcriptomics, peptidomics, pro-
teomics, lipidomics and resulting morphological changes.
Therefore, special care and critical consideration have to be
taken into account when drawing conclusions from these
models.
A major step towards the expansion of sample sizes and
the increased use of post-mortem human tissue is the appli-
cability of MALDI-MS to FFPE brain tissues for detection of
differential protein expression byMALDI-MSI [22], which has
long faced considerable technical difficulties. Proof of prin-
ciple was demonstrated by Stauber et al., who investigated
FFPE brain samples stored for 9 years at room temperature
[22]. Specimens were dewaxed, and 10 m sections were di-
gested using trypsin and analysed. m/z features correspond-
ing to morphological brain structures could be successfully
extracted. Recently, this approach saw a major extension as
access to metabolites in FFPE tissues was demonstrated by
Buck et al. [101]. As the vast majority of human brain tissue
specimen is stored by FFPE, this opens up medical research
archives for the investigation by MALDI-MSI and dramati-
cally increasing the number of samples available for analysis.
Further,with the gradual increase in spatial resolution offered
MALDI-MSI, which now are typically around 50 m for pep-
tides from on-tissue digests and down to 5 m for analytes
not requiring preliminary preparation, such as lipids, neu-
ropeptides and drug compounds ( [21]), single cell layers can
be visualised and limited subcellular information produced.
In conclusion, we identified a range of studies using
MALDI-MSI technology in the fields of AD, PD, schizophre-
nia, and ALS research, with other neurodegenerative and psy-
chiatric disorders (such as depression) completely untapped.
Whilst sample sizes have been small and the focus of many
investigations has been on proving the technique’s applica-
bility to neurological and psychiatric research questions, this
body of literature clearly demonstrates the potential of MS
imaging for future research programmes. Applied to vali-
dated animal models of neurodegenerative and psychiatric
disorders as well as to human samples, the technique should
provide a much needed extension of the neuropathological
toolbox.
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